Singer Capital Markets is delighted to have been appointed as Broker to Sareum Holdings plc with immediate effect.

About Sareum Holdings plc

Sareum is a clinical-stage small molecule company actively involved in developing next generation kinase inhibitors to treat autoimmune diseases and cancer.

Ticker: SAR
Market Cap: £19.3 million*
Website: Click here

*As at 30^th October 2025

Account Team

Investment Banking
Phil DaviesManaging Director,Investment Banking Email | Call	Patrick WeaverAnalyst,Investment Banking Email | Call

Research & Sales
Karl KeeganHead of ResearchEmail | Call	Edward Sham Research Analyst Email | Call	Jonathan Dighe Equity Sales Email | Call

Investor Relations
Kitty McArdleInvestor RelationsEmail | Call